Payment settlements keep generics off the market
To offset generic drug competition, brand manufacturers are increasingly offering generic companies million-dollar payments to delay cheaper generic alternatives from reaching the market. In the latest settlement, Sanofi-Aventis and Bristol-Myers Squibb offered to pay Canadian generic drugmaker Apotex an estimated $40 million to drop its patent challenge and avoid a trial in exchange for delaying introduction of a generic version of the anti-clotting agent clopidogrel (Plavix) until 2011.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Recent Videos
Related Content
